Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in NSCLC

被引：0
|
作者：
De Rosa, V. [1 ]
Iommelli, F. [1 ]
Monti, M. [2 ]
Mainolfi, C. [2 ]
Fonti, R. [1 ]
Del Vecchio, S. [2 ]
机构：
[1] CNR, Inst Biostruct & Bioimages, Naples, Italy
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP303
引用
收藏
页码：S127 / S127
页数：1
相关论文
共 25 条
  • [1] Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    De Rosa, Viviana
    Iommelli, Francesca
    Monti, Marcello
    Mainolfi, Ciro Gabriele
    Fonti, Rosa
    Del Vecchio, Silvana
    EJNMMI RESEARCH, 2016, 6
  • [2] Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Viviana De Rosa
    Francesca Iommelli
    Marcello Monti
    Ciro Gabriele Mainolfi
    Rosa Fonti
    Silvana Del Vecchio
    EJNMMI Research, 6
  • [3] A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance
    Taube, Erika
    Jokinen, Elina
    Koivunen, Peppi
    Koivunen, Jussi P.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (04) : 970 - 979
  • [4] APPLICATION OF 18F-FDG IMAGING IN EARLY EVALUATION OF EFFICACY IN ADVANCED NSCLC
    Wang, H-Q
    RESPIROLOGY, 2011, 16 : 184 - 185
  • [5] Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
    Walter, Annette O.
    Sjin, Robert Tjin Tham
    Haringsma, Henry J.
    Ohashi, Kadoaki
    Sun, Jing
    Lee, Kwangho
    Dubrovskiy, Aleksandr
    Labenski, Matthew
    Zhu, Zhendong
    Wang, Zhigang
    Sheets, Michael
    St Martin, Thia
    Karp, Russell
    van Kalken, Dan
    Chaturvedi, Prasoon
    Niu, Deqiang
    Nacht, Mariana
    Petter, Russell C.
    Westlin, William
    Lin, Kevin
    Jaw-Tsai, Sarah
    Raponi, Mitch
    Van Dyke, Terry
    Etter, Jeff
    Weaver, Zoe
    Pao, William
    Singh, Juswinder
    Simmons, Andrew D.
    Harding, Thomas C.
    Allen, Andrew
    CANCER DISCOVERY, 2013, 3 (12) : 1404 - 1415
  • [6] Preclinical assessment of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
    Simmons, Andrew D.
    Haringsma, Henry J.
    Walter, Annette O.
    Sjin, Robert Tjin Tham
    Weaver, Zoe
    Allen, Andrew
    Harding, Thomas C.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [7] CK-101 (RX518), a mutant-selective inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
    Qian, Xiangping
    Zhu, Yong-Liang
    Cullen, Edward
    Niecestro, Robert M.
    Oliviero, James F.
    CANCER RESEARCH, 2017, 77
  • [8] Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib
    Fang, Wenfeng
    Gan, Jiadi
    Huang, Yihua
    Zhou, Huaqiang
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E274 - E275
  • [9] EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC
    Kasibhatla, Shailaja
    Li, Jie
    Tompkins, Celin
    Vaillancourt, Mei-Ting
    Anderson, Jennifer
    Pferdekamper, AnneMarie Culazzo
    Li, Chun
    Long, Oliver
    McNeill, Mathew
    Epple, Robert
    Liao, Debbie
    Murphy, Eric
    Bender, Steve
    Jia, Yong
    Lelais, Gerald
    CANCER RESEARCH, 2014, 74 (19)
  • [10] Liquid Biopsy in EGFR-Mutated Advanced NSCLC from T790M to MET Amplification: Clinical Implications and Possibilities in the Resistance Setting
    Della Gravara, Luigi
    Battiloro, Ciro
    Avellino, Aniello
    Caputo, Francesca
    D'Aniello, Carmine
    Rocco, Danilo
    JOURNAL OF MOLECULAR PATHOLOGY, 2023, 4 (02): : 81 - 88
123